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Abstract: Maternal HIV-1 status and antiretroviral drug exposure may influence the haematological profiles of infants. 
We recruited infants from 118 uninfected control women and from 483 HIV-1 infected women who received no 
antiretroviral drugs (n=28), or received single-dose Nevirapine (sdNVP) (n=424) or triple-drug combination therapy 
(n=31) to reduce HIV-1 transmission. Blood was drawn from infants within 24 hours of delivery or 6-12 weeks post-
delivery and full blood counts performed using a fully automated AcT-5-diff haematology analyser and reference 
controls. Exposed uninfected (EU; no NVP) differed from control infants only in having lower basophil counts and 
percentages. In all infant groups, leukocyte profiles showed characteristic quantitative changes with age in the first 6 
weeks of life. HIV-1 infected infants displayed by 6 weeks elevations in white blood cells, lymphocyte, monocyte and 
basophil counts, and monocyte and basophil percentages, when compared to EU infants. At birth EU NVP-treated infants 
exhibited elevated monocyte percentages and counts and basophil counts that did not persist at 6 weeks. Interestingly, EU 
newborns of mothers with high CD4 counts (> 500 cells/μl) that had taken sdNVP had significantly elevated white blood 
cell, monocyte and basophil counts when compared to newborn infants of mothers with similar CD4 counts that had not 
taken sdNVP; this was not evident in infants of mothers with CD4 counts <200 cells/μl. These previously undescribed 
features may affect immune response capability in early life and clinical consequences of such changes need to be further 
investigated. 
Keywords: Infant haematological profiles, maternal HIV-1 status, single-dose NVP. 
INTRODUCTION 
  Immune development in neonatal life is unique, being 
shaped by the challenges at the maternal-foetal interface [1] 
and at birth by the transition to the environment outside of 
the uterus which is rich in foreign antigens. Issues relating to 
the effect the maternal immune environment (HIV-1 
exposure and the associated immune dysregulation) has on 
the ontogenic development of an infant’s immune system 
have culminated in numerous studies that have highlighted 
the fact that there are consequences of in utero HIV-1 
exposure and of the antiretroviral prophylaxis given to 
prevent mother-to-child transmission (MTCT) of HIV-1 on 
immune parameters of the newborn. These include 
alterations in haematopoiesis, haematological parameters, T-
cell maturation, immunological reactivity, and imbalances in 
cell populations [2-12]. Our study, which showed in utero 
HIV-1 and pre-birth exposure to single-dose Nevirapine   
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(sdNVP) to significantly increase immune activation in 
infants [13] suggests that the altered maternal immune 
environment, through HIV-1 infection and antiretroviral 
drugs given peripartum, influences the immune system of 
her unborn infant. A murine study has also shown that 
maternal T-helper type 1 responses induced during gestation 
can modulate cell phenotypes and cytokine response 
capabilities in the offspring [14]. The ability of some 
neonates to mount robust HIV-1 specific immune responses 
[15] suggests that at birth infant immune systems are 
sufficiently developed having the necessary immuno-
competent cells and signalling mechanisms in place to 
provide the immune components necessary for developing 
responses that are protective from maternal HIV-1 infection. 
  The increased use of antiretroviral drugs to prevent 
MTCT of HIV-1 is associated with the added risk of 
haematological toxicity in the mother and infant. Concerns 
about the short- and long-term haematological toxicities 
caused by transmission prophylaxis have prompted several 
studies that address issues of safety and possible side effects. 
While results from some short-term studies are reassuring 
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up to 18 months following perinatal exposure [4, 17]. 
Results from other studies have raised concerns over the 
longer term adverse effects of neonatal exposure to 
antiretroviral drugs [6, 18, 19]. 
  Important factors such as antigen dose, microenviron-
ment (which includes exposure to antiretrovirals) and timing 
and extent of antigen exposure will likely influence the 
outcome of the infant’s immune response to subsequent 
antigenic challenge as well as responses to vaccines. During 
pregnancy, innate and adaptive immune responses are altered 
[20], and further dysregulated as a consequence of HIV-1 
infection. The aim of this study was to establish if blood cell 
counts and differentials were altered in infants in early life as 
a consequence of maternal immune status (CD4 count and 
viral load) and antiretroviral drug exposure (particularly 
maternal sdNVP). Given our interest in infant cellular 
immune response capability in early life, we focussed on 
alterations of white blood cell (WBC) counts and differen-
tials (neutrophils, lymphocytes, monocytes, eosinophils, 
basophils; expressed as either an absolute value (counts: 
percentage x total WBC) or as a percentage (differential: 
relative number of each type of WBC in relation to the total 
WBC)). To the best of our knowledge this is the first 
reported study showing that these parameters are affected by 
maternal sdNVP treatment as well as HIV-1 status, 
especially maternal CD4 counts. 
MATERIALS AND METHODS 
Study Population 
  Infants were recruited from mothers that formed part of 
the HIV-1 Protective Immunity and Perinatal Exposure 
Study. Participants included infants born to uninfected 
(control) and HIV-1 infected mothers, recruited at Chris 
Hani Baragwanath Hospital (CHBH), Soweto, South Africa 
and from Coronation Women and Children Hospital 
(CWCH), Johannesburg, South Africa. Women at CHBH 
were enrolled at delivery and blood was collected from their 
infants within 48 hours following delivery. Infants of women 
identified as part of the postpartum voluntary counselling 
and testing program were given sdNVP as post-exposure 
prophylaxis (PEP) and mothers were counselled about infant 
feeding options. These were women that were identified at 
the maternity ward as having delivered live-born infants but 
who had not been tested for HIV-1 at CHBH prior to 
delivering their infants; NVP was administered as PEP to 
infants of women that consented and that were identified as 
being positive. The study subjects who were identified as 
HIV-1 positive during pregnancy and who participated in 
routine prevention of MTCT services received sdNVP before 
delivery. All mothers from CWCH were identified at 6 
weeks post-partum when they returned for postnatal follow-
up services. These mothers received either sdNVP or 
combination antiretroviral therapy (ART) (lopinavir/ritona-
vir, stavudine (d4T), lamivudine (3TC) or efavirenz, d4T, 
3TC) if identified with low CD4 counts early enough during 
pregnancy (combination therapy would have been initiated at 
any stage of pregnancy but adherence in these women may 
not have been complete however, NVP or other ART 
intervention would have been taken prior to delivery). A 
summary of the maternal clinical characteristics and the 
antiretroviral regimens given to the mothers to reduce MTCT 
of HIV-1 are presented in Table 1. Peripheral blood was 
again collected at 6 weeks (for the CHBH enrolees, CWHC 
participants were only recruited at 6 weeks) and 12 weeks if 
possible. Blood was collected from 119 uninfected children 
(twins born to one of the mothers) and these served as 
controls. Blood was processed within 12 hours of collection. 
Written informed consent was obtained from the participants 
and ethical approval was obtained from the Committee for 
Research on Human Subjects of the University of the 
Witwatersrand. 
Sample Processing and Testing 
  Infants born to mothers at CHBH were prospectively 
followed up after birth to determine their HIV-1 status until 
12 weeks. HIV-1 DNA polymerase chain reaction (PCR) 
tests were carried out on infant peripheral blood samples 
collected at 6 weeks (Amplicor, Roche Diagnostic Systems, 
Inc, Branchburg, New Jersey, USA). If the 6 week PCR was 
positive, samples collected on the day of birth were tested to 
establish timing of infection. A positive result at birth was 
used to infer intrauterine transmission and a negative result 
at birth but a positive result at 6 weeks or later was used to 
infer intrapartum transmission. Almost all women avoided 
breastfeeding and those who initiated some breastfeeding 
had all stopped by 6 weeks. Children who remained negative 
at 6 weeks or 12 weeks were considered to be exposed 
uninfected (EU). Infants born to mothers at CWCH were 
tested at 12 weeks and if the PCR was positive the 6 week 
sample was tested. In this group, however, the timing of 
infection could not be determined because birth samples 
were not available. Maternal viral load was measured in 
plasma using the Roche Amplicor RNA Monitor assay 
(Roche Diagnostic Systems, Inc, New Jersey, USA) with the 
lower detection limit of <400 HIV-1 RNA copies/ml. CD4 T 
cell counts were determined using the FACSCount System 
(Becton Dickinson, San Jose, CA). 
  A full blood count was performed on the infant blood 
samples within 12 hours of blood having been drawn from 
patients, using a fully automated AcT-5-diff haematology 
analyser (Beckman Coulter Inc, Fullerton, CA) according to 
the manufacturer’s protocol. Reference controls (low, 
medium and high; Beckman Coulter Inc, Fullerton, CA) 
were routinely used to confirm and monitor instrument 
accuracy and performance by providing measurements for 
counting, sizing, haemoglobin determination and white 
blood cell differentiation. Low counts were confirmed with 
manual differentials. Specimen results were accepted when 
the control ranges fell within those specified for the 
reference controls. Specimens whose results fell out of the 
range of determination were diluted (1:2 or 1:4 in saline) and 
the dilution factor taken into account when leukocyte counts 
for these samples were analysed. A sample report was 
automatically generated for each specimen with the data 
being presented as a percentage and an absolute number per 
microlitre.  Reference values used for the white blood cell 
counts (neutrophils, lymphocytes, monocytes, eosinophils 
and basophils) come from the Department of Haematology, 158    The Open AIDS Journal, 2010, Volume 4  Schramm et al. 
National Health Laboratory Service (NHLS), Chris Hani 
Baragwanath and Braamfontein Laboratories Service 
Handbook, 2006-2007 [21]. We refer to these values as 
DISA reference values. DISA serves as the laboratory 
information system used by the NHLS. These DISA 
reference tables represent baseline data applicable to the 
South African population. Haematological parameters 
recorded are shown in column 1 of Table 2. 
Statistical Tests 
 The  non-parametric  Mann-Whitney  U test was used to 
determine whether there were any significant differences in 
the proportions and absolute cell counts between the infant 
study groups. Statistical analyses were performed using 
SPSS software (version 17.0, SPSS Inc., Chicago, IL). All 
statistical tests were two-tailed and considered significant at 
P<0.05. 
RESULTS 
Clinical Characteristics of the HIV-1-Seropositive 
Mothers and their Infants 
  The maternal clinical characteristics and the antiretroviral 
regimens given to the mothers to reduce MTCT of HIV-1 of 
the infants included in this study are presented in Table 1. At 
birth, viral loads and CD4 counts were not significantly 
different between mothers that did not take NVP and those 
that did (P=0.688 and P=0.294, respectively). Mothers given  
 
 
triple drugs were only recruited at either 6 weeks or 12 
weeks and their viral loads and CD4 counts were 
significantly lower than those of NVP unexposed (P=0.001 
and P<0.001 respectively) and NVP treated mothers 
(P<0.001 and P<0.001 respectively). 
Changes in Haematological Profiles within the First Six 
Weeks of Life 
 Although maturational abnormalities have been 
associated with intrauterine exposure to HIV-1, quantitative 
changes (birth to 6 weeks) in the infant cell type counts, 
consistent with the maturational development expected in 
infants after birth, was observed amongst all infant groups 
including those exposed to maternal NVP i.e. control, 
exposed uninfected (EU) no NVP, EU NVP (Table 2) and 
infected NVP (Table 3) infants. When comparing control 
and EU (no NVP) infants, blood cell profiles were not 
different at birth or at 6 weeks (with the exception of 
basophil counts (P=0.005) and percentages (P=0.009), which 
were lower in EU infants (no NVP) at birth) (Table 2). As 
birth samples were taken within 48 hours of delivery; 
reference ranges are therefore provided for both range 
categories for comparison (birth and 1 day – 1 week). 
Irrespective of infant infection status (controls, EU or 
infected) and maternal drug regimen, most infants at birth, 
tended to have normal ranges of neutrophil, lymphocyte, 
monocyte, basophil and eosinophil counts when compared to 
DISA reference ranges. 
 
 
Table 1.  Cohort Summary of the Mothers of Infants Recruited at Chris Hani Baragwanath Hospital, Soweto, South Africa and 
from Coronation Women and Children Hospital, Johannesburg, South Africa 
 
HIV-1 Infected Mothers 
ART Regimen  Controls 
No Drug  Monotherapy (NVP Only)  Triple Therapy
3 
N 118
1   28   424  31 
Mean (Standard Deviation) (n/N) 
Maternal CD4
+ T-cell count  991 (344) (6/20)
2  575 (228) (27/28)  482 (261) (422/424)  221 (154) (31/31) 
Maternal age (y)  25 (6.4) (20/20 )
 2  28 (5.8) (27/28)  28 (5.2) (422/424)  29 (5.5) (31/31) 
Infant birth weight (g)  3002 (461) (20/20)
 2  2815 (503) (28/28)  3049 (451) (422/424)   3004 (504) (31/31) 
Median (IQR) (n/N) 
 Maternal viral load (log10)  uninfected  3.9 (2.8-4.4) (28/28)  3.98 (3.3-4.7) (419/424)  2.6 (2.6-2.8) (31/31) 
% (n/N) 
Primiparity 45  (9/20)
 2  21 (6/28)  30 (45/424)  100 (31/31) 
Infant sex (male)  58 (11/20)
 2  39 (11/28)  49 (208/424)  45 (14/31) 
Preterm (<37 wk)  15 (3/20)
 2  15 (4/28)  4 (15/424)  3 (1/31) 
Vaginal delivery  100 (20/20)
 2  86 (24/28)  88 (370/424)  77 (24/31) 
N: group size – no distinction is made between sampling time points i.e. birth, 6 weeks or 12 weeks or the hospital sites. 
IQR: interquartile range (25
th and 75
th percentiles). 
n/N: number of cases tested from the group. 
1One of the control mothers had twins i.e. infant number = 119. 
2Limited clinical data available on the control patients. 
3Mothers given triple-drugs (lopinavir/ritonavir, stavudine (d4T), lamivudine (3TC) or efavirenz, d4T, 3TC) were only recruited at 6 weeks or 12 weeks. 
Note: South African PMTCT guidelines have been criticised for commencing comprehensive management for all pregnant women with highly active antiretroviral therapy 
(HAART) in WHO stage IV with CD4 counts 200 cells/μl. On November 30th 2009 the World Health Organization announced new recommendations that replace previous 
guidelines for low and middle-income countries that everyone diagnosed with HIV infection should start treatment when their CD4 count falls below 350 cells/μl. Effect of Maternal HIV-1 Status and Antiretroviral Drugs  The Open AIDS Journal, 2010, Volume 4    159 
   
Table 2.  Haematology Profiles of Birth and of 6 Weeks Control Infants and Exposed Uninfected Infants that were Not Exposed to 
Maternal NVP or that Received sdNVP or Triple Antiretroviral Therapy to Reduce MTCT of HIV-1 
 
Infant Group  Birth
  6 Weeks 
Haematologic  
Parameter  
Median 
(IQR) 
(Min;Max) 
DISA  
Reference  
Ranges  
(Infants  
Birth)
# 
DISA  
Reference  
Ranges 
(Infants 
 1 day –  
1 Week)
# 
Control 
 No 
 NVP 
EU 
 No 
 NVP 
EU 
 NVP 
DISA  
Reference  
Ranges  
(Infants 
 1 – 6  
Months) 
Control  
No  
NVP 
EU 
 No 
 NVP 
EU 
NVP 
EU 
Triple  
Therapy 
No. Of  
Infants     112  16  113   34  20  258  13 
Haemoglobin  
(g/dL)  18.0-27.0  16.0-25.5 
17 
(15.5-18.6) 
(3.9;22.5) 
16.8 
(15.5-18.8) 
(14.2;19.5) 
17.6 
(15.9-19.5) 
(10.9;23) 
10.0-15.0 
11.8 
(10.5-12.8) 
(10.1;14) 
10.8 
(9.8-11.5) 
(6.8;13.5) 
11.2 
(10.5-12) 
(2;16.3) 
11.3 
(10.7-11.7) 
(9.5;13.1) 
MCV 
(fL) 
109 
(Av) 
104 
(Av) 
106 
(102-109.8) 
(91;124) 
108.5 
(96.5-110.8) 
(84;112) 
108 
(102-111) 
(82;118) 
78 
(Av) 
92 
(87-95) 
(72;103) 
92 
(86-93.8) 
(71;101) 
92 
(88-95) 
(70;190) 
98 
(96.5 -100) 
(87;105) 
Absolute Counts (/L) 
Platelets 
(x10
3)  140-400  140-400 
235.5 
(183.8-
306.8) 
(41;467) 
242.5 
(139.5-
268.3) 
(19;569) 
237 
(178.5-
280.5) 
(13;413) 
140-400 
427 
(317.5-
482.5) 
(177;711) 
429.5 
(375-
538.8) 
(147;840) 
420 
(334-529) 
(3.1;805) 
421 
(333.5-
600) 
(136;692) 
RBC 
(x10
6)  4.8-7.1  4.5-6.4 
5.1 
(4.5-5.4) 
(1;6.7) 
4.8 
(4.5-5) 
(3.8;6) 
4.9 
(4.4 -5.3) 
(3;6.8) 
3.9-5.3 
3.8 
(3.5-4.1) 
(3.1;4.7) 
3.5 
(3.1-3.7) 
(2.1;5.2) 
3.5 
(3.2-3.9) 
(0.7;306) 
3.3 
(3.1-3.4) 
(3-3.9) 
WBC 
(x10
3)  9.0-30.0  5.0-21.0 
16 
(12.9-20.4) 
(7.7;168) 
13.8 
(10.5-18.3) 
(7.9;20.4) 
15.6 
(12.9-19.3) 
(6.6;33) 
6.0-17.5 
7.8 
(6.3-9.6) 
(3.1;17.8) 
9.1 
(7.4-12.1) 
(4.4;18.6) 
9.1 
(7.3-11.1) 
(0.1;36.3) 
10.4 
(7.6-11) 
(5.4;15.7) 
Neutrophils 
(x10
3)  6.0-26.0  1.5-10.0 
9.1 
(6.9-12.5) 
(2.5;20.6) 
7.9 
(6.2-10.6) 
(4.3;13.4) 
9.1 
(7-11.1 ) 
(2.8;20.9) 
1.0-8.5 
1.8 
(1.3-2.4) 
(0.3;4.1) 
2 
(1.5-2.9) 
(0.3;4.3) 
1.8 
(1.4-2.7) 
(0.03;11.5) 
1.9 
(1.2-3.9) 
(0.56;4.8) 
Lymphocytes 
(x10
3)  2.0-11.0  2.0-17.0 
3.8 
(3.1-4.5) 
(1.4;7.4) 
3.6 
(3.1-4.1) 
(1.3;6.9) 
3.6 
(2.9-4.4) 
(1.5;7.3) 
4.0-13.5 
4.6 
(3.7-6.1) 
(2.1;12.5) 
5.7 
(4.5-7.6) 
(2-11.5) 
5.4 
(4.5-7) 
(0.05;24.5) 
5.1 
(4.7-7.4) 
(4;8.7) 
Monocytes 
(x10
3)  0.4-3.1  0.3-2.7 
1.4 
(1.0-1.8) 
(0.3;4.3) 
1.2 
(1-1.6) 
(0.3;2.6) 
1.6 
(1.2-2.1) 
(0.06;4.1) 
0.1-1.3 
0.72 
(0.48-0.97) 
(0.26;1.9) 
0.93 
(0.65 
(1.3) 
(0.07;2.6) 
1 
(0.7-1.3) 
(0.01;6.4) 
0.88 
(0.65-1.1) 
(0.43;2.4) 
Eosinophils 
(x10
3)  0.02-0.85  0.07-1.10 
0.29 
(0.19-0.4) 
(0.1;1.3) 
0.27 
(0.19-0.36) 
(0.11;0.53) 
0.27 
(0.2-0.39) 
(0.04;0.6) 
0.07-0.75 
0.34 
(0.21-0.47) 
(0.05;1.8) 
0.24 
(0.14-0.29) 
(0.1;0.82) 
0.24 
(0.16-0.36) 
(0;2.3) 
0.2 
(0.13-0.33) 
(0.06;0.8) 
Basophils 
(x10
3)  0-0.64  0-0.25 
0.6 
(0.3-1.2) 
(0.05;7.4) 
0.3 
(0.12-0.65) 
(0.03;1.4) 
0.5 
(0.23-1.3) 
(0.04;4.1) 
0-0.2 
0.11 
(0.06-0.15) 
(0.02;0.4) 
0.12 
(0.07-0.21) 
(0.04;0.48) 
0.1 
(0.07-0.16) 
(0.02;2.26) 
0.12 
(0.09-0.18) 
(0.05-0.31) 
Blood Differential (%) 
Neutrophils  -  - 
57.2 
(51.2-64.6) 
(6.7;74.6) 
57.9 
(53.1-65.9) 
(49.5;77.2) 
59.3 
(52.6-65) 
(37.3;73.9) 
- 
22.1 
(18.6-28.6) 
(4.9;41.3) 
22.2 
(17.6-29.3) 
(5.1;38.8) 
21.4 
(17.3-27.5) 
(3.6;52.7) 
24.4 
(12.3-31) 
(9.2;43.9) 
Lymphocytes -  - 
24.1 
(18.9-30.4) 
(8.7;47.8) 
28.5 
(19.6-32.3) 
(12.2;39.2) 
23.1 
(18.2-28.4) 
(10.7;49.7) 
- 
64.1 
(52.7-67.1) 
(43.6;74.2) 
62.5 
(58.5-69.2) 
(44.8;71.5) 
62.6 
(56.3-68) 
(32.8;86.8) 
65.1 
(53.5-72.9) 
(43.2;78.3) 
Monocytes -  - 
8.9 
(7.3-10.4) 
(2.5;16.1) 
8.6 
(8.2-10.6) 
(4.2;13.3) 
10.3 
(9.1-12.2) 
(0.9;22) 
- 
8.6 
(7.5-11.2) 
(5.1;19.4) 
10.7 
(8.3-13.2) 
(0.6;15.2) 
10.6 
(8.8-12.9) 
(0.7;31.7) 
9.2 
(7.7-11.8) 
(5.8;17.3) 
Eosinophils -  - 
1.7 
(1.3-2.4) 
(0.7;9.3) 
2 
(1.4-2.5) 
(0.9;3.8) 
1.7 
(1.3-2.3) 
(0.5;4.9) 
- 
4.1 
(2.6-5.8) 
(0.5;20) 
2.3 
(1.4-3.6) 
(0.9;12.7) 
2.7 
(1.7-3.8) 
(0.1;25.5) 
2.3 
(1.9-2.6) 
(0.8;7.4) 
Basophils -  - 
3.5 
(2-8.1) 
(0.5;41.6) 
2.1 
(1.1-4.2) 
(0.4;7.6) 
3.2 
(1.6-8.8) 
(0.5;21.4) 
- 
1.2 
(0.85-1.7) 
(0.5;5.3) 
1.3 
(0.8-1.8) 
(0.6;11.1) 
1.1 
(0.9-1.4) 
(0.3;38.3) 
1.2 
(1-1.65) 
(0.8;3.3) 
IQR: interquartile range (25
th and 75
th percentiles). 
Min: lowest value for the haematologic parameter; max: highest value for the haematologic parameter. 
#DISA reference ranges are shown for two infant groups namely birth and 1 day to 1 week. 
Av: average value. 160    The Open AIDS Journal, 2010, Volume 4  Schramm et al. 
Maturation Profiles of Infants are Affected by HIV-1 
Infection 
  At birth, leukocyte profiles were not significantly 
different between EU infants and infected infants exposed to 
maternal sdNVP (Table 3 and Fig. 1). By 6 weeks however, 
HIV-1 infected infants had significantly higher WBC counts 
(P=0.002), lymphocyte counts (P=0.017), monocyte 
percentages (P=0.011), monocyte counts (P<0.001), basophil 
percentages (P<0.001) and basophil counts (P<0.001) 
compared to EU infants (Table 3 and Fig. 1). At 12 weeks  
 
Table 3.  Maturational Changes (Birth to 12 Weeks) Amongst Exposed Uninfected and HIV-1 Infected Infants whose Mothers 
were Given NVP 
 
Infant Group  Birth NVP  6 Weeks NVP  12 Weeks NVP 
Haematologic Parameter Median (IQR)  
(min;max)  EU HIV-1  Infected  EU HIV-1  Infected  EU HIV-1  Infected 
No. of infants  113  15  258  24  171  20 
Haemoglobin 
(g/dL) 
17.6 
(15.9-19.5) 
(10.9;23) 
17.6 
(15.8-19.1) 
(9.6;21.3) 
11.2 
(10.5-12) 
(2;16.3) 
11 
(9.7-12.3) 
(5;18) 
11.6 
(10.9-12) 
(6;14.8) 
11 
(10.6-11.4) 
(8.9;12.1) 
MCV 
(fL) 
108 
(102-111) 
(82;118) 
106 
(103-108) 
(93;112) 
92 
(88-95) 
(70;190) 
88 
(85-93.8) 
(79;101) 
83 
(80-86) 
(69;92) 
84 
(81-85.8) 
(75;89) 
Absolute Counts (/L) 
Platelets 
(x10
3) 
237 
(178.5-280.5) 
(13;413) 
204 
(173-261) 
(41;283) 
420 
(334-529) 
(3.1;805) 
362.5 
(304-451.3) 
(97;676) 
442 
(363-532) 
(35;819) 
260 
(190.8-383.3) 
(35;544) 
RBC 
(x10
6) 
4.9 
(4.4 -5.3) 
(3;6.8) 
5 
(4.3-5.2) 
(2.9;5.7) 
3.5 
(3.2-3.9) 
(0.7;306) 
3.6 
(3.2-3.9) 
(1.5;4.9) 
4.1 
(3.8-4.3) 
(2;5.2) 
3.8 
(3.7-3.9) 
(3.1;4.2) 
WBC 
(x10
3) 
15.6 
(12.9-19.3) 
(6.6;33) 
16.3 
(12.4-21.8) 
(9.1;31) 
9.1 
(7.3-11.1) 
(0.1;36.3) 
12.4 
(8.5-16) 
(2.8;25) 
8.6 
(7.1-10.7) 
(0.7;24) 
9.3 
(6.7-12.9) 
(0.1;16.3) 
Neutrophils 
(x10
3) 
9.1 
(7-11.1 ) 
(2.8;20.9) 
9.4 
(8.3-12.5) 
(4.5;15.5) 
1.8 
(1.4-2.7) 
(0.03;11.5) 
2.3 
(1.5-3) 
(0.2;4.8) 
1.8 
(1.2-2.5) 
(0.14;7.7) 
1.7 
(1.4-2.2) 
(0.54;4.9) 
Lymphocytes 
(x10
3) 
3.6 
(2.9-4.4) 
(1.5;7.3) 
3.5 
(3.1-4.8) 
(1.9;9.7) 
5.4 
(4.5-7) 
(0.05;24.5) 
7 
(5.3-9.9) 
(1.8;13.3) 
5.5 
(4.3-7.1) 
(0.5:14.5) 
5.5 
(3.5-7.1) 
(0.1;12.1) 
Monocytes 
(x10
3) 
1.6 
(1.2-2.1) 
(0.06;4.1) 
1.6 
(1.1-2.1) 
(0.56;2.5) 
1 
(0.7-1.3) 
(0.01;6.4) 
1.4 
(1.1-2.1) 
(0.2;6) 
0.79 
(0.57-1.1) 
(0.04;3) 
1.3 
(0.56-1.5) 
(0.02;3.4) 
Eosinophils 
(x10
3) 
0.27 
(0.2-0.39) 
(0.04;0.6) 
0.28 
(0.17-0.33) 
(0.05;0.5) 
0.24 
(0.16-0.36) 
(0;2.3) 
0.35 
(0.13-0.49) 
(0.06;4.7) 
0.24 
(0.13-0.35) 
(0.01;1.2) 
0.3 
(0.1-0.6) 
(0.02;2.3) 
Basophils 
(x10
3) 
0.5 
(0.23-1.3) 
(0.04;4.1) 
0.47 
(0.15-1.38) 
(0.08;3.9) 
0.1 
(0.07-0.16) 
(0.02;2.26) 
0.28 
(0.13-0.33) 
(0.04;1.22) 
0.1 
(0.06-0.14) 
(0;0.48) 
0.16 
(0.09-0.26) 
(0.01;0.57) 
Blood Differential (%) 
Neutrophils 
59.3 
(52.6-65) 
(37.3;73.9) 
60 
(51.4-66.1) 
(39.4;76.4) 
21.4 
(17.3-27.5) 
(3.6;52.7) 
18.8 
(15.1-25.2) 
(6.3;41.1) 
20.3 
( 14.9-27.6) 
(4.1;65.1) 
20 
(12.2-25.1) 
(8.5;40) 
Lymphocytes 
23.1 
(18.2-28.4) 
(10.7;49.7) 
21.5 
(18.5-31.8) 
(13.1;44.2) 
62.6 
(56.3-68) 
(32.8;86.8) 
57.7 
(51.6-65.9) 
(44.6;79.7) 
65.8 
(57.6-72.1) 
(23.7;86.9) 
60 
(50.4-69.9) 
(44.8;78.9) 
Monocytes 
10.3 
(9.1-12.2) 
(0.9;22) 
10.2 
(9-11.1) 
(4.5;14.1) 
10.6 
(8.8-12.9) 
(0.7;31.7) 
12.4 
(10.3-14.5) 
(4.1;31.5) 
8.6 
(6.6-11.3) 
(0.8;22.9) 
11.5 
(9.4-15.7) 
(7;23.6) 
Eosinophils 
1.7 
(1.3-2.3) 
(0.5;4.9) 
1.6 
(1.2-1.9) 
(0.5;2.3) 
2.7 
(1.7-3.8) 
(0.1;25.5) 
2.5 
(1.4-5.2) 
(0.3;28.2) 
2.5 
(1.6-4.2) 
(0.2;15.4) 
3 
(1.7-6.9) 
(0.2;17.4) 
Basophils 
3.2 
(1.6-8.8) 
(0.5;21.4) 
2.9 
(1.4-8.6) 
(0.6;12.6) 
1.1 
(0.9-1.4) 
(0.3;38.3) 
2 
(1.5-2.5) 
(0.6;5.1) 
1 
(0.9-1.3) 
(0.4;3.3) 
1.7 
(1.3-2.3) 
(0.7;9.7) 
IQR: interquartile range (25
th and 75
th percentiles). 
Min: lowest value for the haematologic parameter; max: highest value for the haematologic parameter. Effect of Maternal HIV-1 Status and Antiretroviral Drugs  The Open AIDS Journal, 2010, Volume 4    161 
 
Fig. (1). Leukocyte maturation profiles of HIV-1 exposed 
uninfected and HIV-1 infected infants exposed to NVP given to 
HIV-1 infected mothers to reduce maternal transmission of HIV-1. 
Data are presented as medians (horizontal bar), 25
th and 75
th 
percentiles (boxes), and 10
th and 90
th percentiles (bars). Significant 
differences between groups and sample numbers per group are 
indicated. The South African DISA reference ranges for infants 1 
day to 1 week and 1 month to 6 months are indicated by bars 
appearing next to the control infant data. 
monocyte percentages and monocyte counts were still 
increased (P=0.001 and P=0.005 respectively) as were 
basophil percentages and basophil counts (P<0.001 and 
P=0.043 respectively) relative to EU infants (Table 3 and 
Fig.  1). In addition RBC counts (P=0.002), HgB levels 
(P=0.008) and platelet counts (P<0.001) were significantly 
reduced in HIV-1 infected infants compared to EU infants at 
12 weeks (Table 3). 
Maturation Profiles of Exposed Uninfected Infants are 
Affected by Exposure to Maternal sdNVP 
  Having shown that infant leukocyte profile was not 
significantly affected by exposure to HIV-1 in the absence of 
HIV infection (EU infants) we wanted to establish whether 
exposure to maternal sdNVP influences blood counts. We 
show that haematological profile changes, consistent with 
maturational development, occurs irrespective of maternal 
sdNVP exposure (EU no NVP compared to EU NVP groups; 
Table  2) however, monocyte percentages (P=0.016), 
monocyte counts (P=0.039) and basophil counts (P=0.033) 
were significantly elevated at birth amongst EU NVP treated 
infants versus untreated EU infants (Table 2). By six weeks 
of age, there were no significant differences in the leukocyte 
profiles of no NVP and NVP exposed infant groups (Table 
2). Infants exposed to maternal triple-drug therapy had 
significantly reduced RBC counts (P=0.024) compared to 
maternal sdNVP exposed infants. By 12 weeks only basophil 
percentages in triple-drug exposed infants remained 
significantly higher than those of NVP exposed infants 
(P=0.018) (data not shown). 
  Gender (male versus female infants) was not found to 
influence haematological values in the control, EU 
(unexposed or exposed to combination therapy) or HIV-1 
infected (NVP exposed) infants at birth, 6 weeks or 12 
weeks (where these comparisons were possible based on 
sample size). Curiously, at birth EU infant boys (n=49) 
exposed to maternal sdNVP had significantly higher 
lymphocyte percentages (P=0.035) but significantly reduced 
RBC counts (P=0.020), basophil counts (P=0.012) and 
percentages (P=0.015) compared to EU infant girls (n=64) 
exposed to maternal sdNVP (data not shown). These data 
could imply that haematological values of male and female 
infants may be uniquely affected by short courses of NVP 
exposure. 
At Birth Infant White Blood Cell Counts and 
Differentials are Influenced by Maternal CD4 Count 
  The white blood cell counts and differentials of EU NVP-
exposed infants were compared when stratified on the basis 
of maternal CD4 counts, namely, <200 cells/μl; 200-500 
cells/μl (intermediate CD4 counts) and >500 cells/μl (normal 
- counts range from 500-1500 x 10
6/l). We found WBC and 
basophil, neutrophil and monocyte counts to be significantly 
lower amongst infants whose mothers had low CD4 counts 
(<200 cells/l) relative to those with high CD4 counts (>500 
cells/μl). Basophil percentages followed a similar pattern and 
for monocyte percentages those with intermediate CD4 
counts (200-500 cells/l) had the lowest values (Fig. 2A). 
EU infants not exposed to maternal sdNVP also tended to 
have lower levels of lymphocyte, monocyte, eosinophil and 
basophil percentages and lymphocyte, eosinophil and 
basophil counts when born to mothers with CD4 counts 200-
500 cells/l compared to those born to mothers with higher 
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>500 cells/μl (insufficient sample numbers for <200 cells/μl 
group; data not shown). We found no significant differences 
in white blood cell counts and differential of EU infants 
when separated on the basis of maternal viral load that is, 
viral loads <50,000 RNA copies/ml or >50,000 RNA 
copies/ml (high) (data not shown). 
  Among EU infants born to mothers with CD4 counts 
>500 cells/μl (Fig. 2B), WBC, monocyte percentages and 
monocyte and basophil counts were significantly elevated 
but lymphocyte and eosinophil percentages significantly 
decreased amongst those infants exposed to the dose of NVP 
given to the mothers compared to NVP-unexposed EU 
infants (Fig. 2B). Alterations in numbers or proportions of 
certain cell types in these EU infants may be a feature of 
higher maternal CD4 counts, with some of these changes 
further accentuated in the presence of exposure to maternal 
sdNVP. 
DISCUSSION 
  Pregnancy is characterized by a change in the balance of 
the innate and adaptive immune responses, more 
specifically, changes in cell counts, phenotypes, functions 
and soluble factors [20]. This altered balance is further 
impacted on by HIV-1 infection and with the use of 
antiretroviral drugs to prevent MTCT of HIV-1. While there 
is no vascular continuity between mother and foetus the 
transplacental passage of maternal components is known to 
occur. In fact the transplacental passage of IgG [22], low 
molecular weight substances e.g. amino acids [23] and 
inorganic ions [24] as well as inflammatory cytokines 
(interleukin (IL)-6) [25] and antiretrovirals [26] is well 
recognised. Neonatal life is a very unique developmental 
time, where the peripheral pool is stimulated and develops 
memory (either to foreign- or to self-antigen). Regulation 
and development of both the innate and adaptive immune 
responses in an infant therefore requires the presence and 
interaction of different cell types and several soluble factors 
e.g. cytokines and chemokines. Considering the fetomaternal 
interface, the dysregulation of maternal immune responses 
associated with pregnancy and HIV-1 infection, we aimed to 
describe alterations in haematological parameters 
(particularly white blood cell counts and differentials) of 
 
Fig. (2). Leukocyte profiles of newborn infants differentiated according to maternal CD4 counts (<200 cells/μl, 200-500 cells/μl and >500 
cells/μl). Mothers of these infants were given sdNVP to reduce MTCT of HIV-1 (A). Significant differences between leukocyte profiles of 
EU infants at birth born to mothers with CD4 counts >500 cells/μl that had either not taken sdNVP or had taken sdNVP to reduce MTCT of 
HIV-1 are presented in (B). Data are presented as medians (horizontal bar), 25
th and 75
th percentiles (boxes), and 10
th and 90
th percentiles 
(bars). Significant differences between groups and sample numbers per group are indicated. 
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infants born to HIV-1 infected mothers, mainly in the 
context of exposure or not to maternal sdNVP. We further 
questioned whether maternal immune status might affect the 
cell profiles of their matched newborns. As some mothers 
did receive triple drug therapy their infants were also 
included for study from 6 weeks of age. 
  As expected there were age-dependant maturational 
changes (innate to adaptive immunity) demonstrated by the 
quantitative changes in the peripheral blood of newborns 
from all infant groups (uninfected, EU, HIV-1 infected). In 
particular, neutrophils (indicative of innate immune 
responses) predominated at birth whilst lymphocytes 
(indicative of a developing adaptive immune system) 
prevailed by 6 weeks. We found no significant differences 
between haematological values of control male and female 
infants or between HIV-1 exposed uninfected male and 
female infants whose mothers were not given sdNVP or that 
were given combination therapy. A study conducted on 
Malawian neonates has similarly reported no haematological 
variation between male and female neonates (males, n=177; 
females n=189) [27]. However, sdNVP given to mothers to 
reduce MTCT appeared to influence male and female blood 
parameters differentially. This intriguing interaction should 
be investigated in other cohorts. 
  Several studies have shown Africans may have different 
cell count profiles [28-31] and it is important that what may 
be normal ranges for a particular population group be used as 
the appropriate frame of reference. We therefore used tables 
with reference ranges suitable for South African infants. 
Although neutropenia is more commonly associated with 
AZT therapy it has been described in infants given NVP 
[32]. However, our study which only examined effects of 
maternal HIV-1 and drug exposures up to 12 weeks after 
birth, failed to demonstrate any association between short-
course monotherapy or combination therapy and lower 
neutrophil counts, unlike other reported studies [4, 8, 10]. 
Studies conducted in Europe [4] and the United States [8] 
have indicated that perinatal exposure to antiretrovirals 
results in significant changes in haematological parameters 
observed in infants, many of which may persist up to 2 years 
of age. However, studies differ in the haematological 
parameters that remain affected for this time period. 
  With the exception of the basophil counts and 
percentages which were reduced in EU infants, our study 
shows no differences in haematological parameters at birth 
when comparing control infants to EU (no NVP) infants, 
suggesting that exposure to HIV-1 or other factors in utero 
reduces basophil numbers at birth, possibly due to altered 
signals that may affect trafficking of basophils from bone 
marrow to the periphery. This reduction relative to controls 
was not maintained at 6 weeks. It is not clear if this would 
have been maintained had there been no sdNVP given to the 
infant as PEP following birth, as comparisons between EU 
infants with and without maternal sdNVP exposure revealed 
elevations in monocyte percentages and counts and basophil 
counts in NVP-exposed neonates; these differences were 
however not maintained at 6 weeks of age. Overall, it 
appears that short exposure to NVP at birth has transient 
effects on immune cell parameters. It would be important in 
future to establish if longer regimens of drug treatments may 
maintain elevations of various cell types in the peripheral 
circulation. 
  Triple drug therapy decreased RBC counts at 6 weeks 
and increased basophil percentages at 12 weeks relative to 
sdNVP EU infants. The differences between EU infants and 
HIV-1 infected infants, assessed in sdNVP exposed infants, 
was most apparent at 6 weeks of age where WBC counts 
overall were increased, this being the result of expansions of 
lymphocytes, monocytes and basophils. The latter two cell 
type increases were maintained at 12 weeks with 
accompanying reductions in RBC counts, HgB levels and 
platelet counts. Therefore HIV-1 infected infants, not 
unexpectedly, showed more progressive changes over time 
in haematological parameters and these changes are a likely 
consequence of chronic immune activation [13]. 
  Perhaps the most intriguing result was that when HIV-1 
infected mothers were stratified according to CD4 cell count, 
lower CD4 cell counts (200-500 cells/μl) were associated 
with newborn decreases in white blood cell differentials of 
lymphocyte, monocyte, eosinophil and basophil percentages 
and lymphocyte, eosinophil and basophil counts. Some of 
these alterations were even further accentuated by exposure 
to maternal sdNVP viz. WBC, monocyte and basophil counts 
and monocyte percentages were increased, while lymphocyte 
and eosinophil percentages were significantly decreased. 
These findings raise some interesting questions. 
  It is notable that uninfected infant mortality and 
morbidity has been significantly associated with HIV-1 
infected mothers with advanced disease (low CD4 counts) 
[33]. It may be expected that this greater risk to the infant 
may involve effects of maternal health status on the 
maturational development of infant blood parameters and 
also immunological deficiencies influencing such factors as 
the passively acquired maternal antibodies. Although we 
observed alterations in infant cell counts by maternal CD4 
counts, infants born to mothers with high CD4 counts (>500 
cells/ul), with or without NVP exposure, tended to have the 
most elevations relative to expected norms. The infant 
leukocyte parameters we measured are quite non-specific 
and it is interesting that variations by maternal CD4 count 
were detected at all. We speculate that the data can be 
explained in the context of an “anergy” that exists in the EU 
infants born to mothers with low CD4 counts (<200 cells/l), 
in that these infants although likely exposed to more HIV-1 
because maternal viral loads are generally higher, are unable 
to respond in a similar fashion to their counterparts born to 
mothers with higher CD4 counts and more robust immune 
systems. It is interesting that such an “anergy” may exist in 
these uninfected infants merely through being born to a 
mother with advanced disease. It may be that a lack of 
response to exposure in this way may alter their immune 
capability to challenge. 
  On the other hand, increases in certain white blood cell 
counts and differentials may also have consequences on the 
immune (innate and adaptive) capability of infants. Findings 
here suggest that NVP may actually influence responses 164    The Open AIDS Journal, 2010, Volume 4  Schramm et al. 
possibly favouring innate immune capacity over adaptive 
(reduced proportions of lymphocytes at birth). Furthermore, 
higher basophil counts are often associated with Th2-related 
responses [34] and their elevations may be indicative of a 
more prominent Th2 milieu. Could NVP exert a protective 
effect beyond its direct role as an antiviral through 
enhancing innate as opposed to adaptive responses, or 
through prolonging a Th2 immune milieu? It would be 
important in future to establish which lymphocyte subsets 
are altered where proportions of overall lymphocytes are 
decreased, however if due to reductions in numbers of T 
cells this might help explain why HIV-specific responses 
detectable in EU infants are elusive to detection in the 
context of sdNVP exposure [35], and such responses are 
reduced in NVP-exposed mothers [36]. A more Th2 oriented 
environment may also not favour detection of HIV-specific 
Th1 responses. 
  A number of studies have raised concerns over the issue 
of increased frequencies of NVP-induced adverse events 
(hepatotoxicity and rash) among pregnant HIV-1 infected 
women [37, 38]. Hepatotoxicity has been more often 
associated with higher CD4 counts (>250 cells/μl) [39, 40]. 
Another interpretation of our data may be that more subtle 
changes of allergy-type responses may be demonstrable in 
peripheral blood of women with high CD4 cell counts and 
their matched infants (given their genetic relatedness one 
might expect similar responses). It is particularly interesting 
that throughout our analyses basophils emerge as a cell type 
affected by HIV-1 exposure and infection and NVP and 
triple drug therapy. Basophils represent only 0.01% to 0.03% 
circulating leukocytes and characteristically are histamine 
containing metachromatic granulocytes which when 
activated exocytose their granule constituents and slowly 
generate and release cytokines, chemokines and arachidonic 
acid metabolites. They, along with tissue-based mast cells 
play an important role in IgE-mediated inflammatory 
responses. Recent studies in mice have reported basophils to 
be essential for B-cell memory responses by promoting T 
helper cell-2 dependent B-cell help [41]. Why NVP might 
enhance basophil and monocyte counts while decreasing 
lymphocytes and eosinophil numbers is unclear, but given 
our previous report of evidence of increased immune 
activation (elevated plasma soluble activation markers in 
both mothers and matched infants) through the short 
exposure to NVP given at the onset of delivery [13] it is 
likely that trafficking of cells would occur differentially 
culminating in alterations of cell compositions in the 
peripheral circulation. 
  In conclusion, this study has shown that maternal HIV-1 
disease status and antiretroviral drug exposure influence 
infant haematological parameters which may have 
implications for infant immune response capability. 
Although these effects may be transient it is not clear how 
these differences impact (whether at all) on an infant’s 
ability to respond to HIV-1 challenge or control HIV-1 
viraemia or if they influence the induction of protective 
immune responses by vaccines in early life. Furthermore, 
this study adds to the evidence purporting the importance of 
improving maternal health and providing treatment options 
that reduce maternal viral load and increase CD4 counts. 
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